MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MediWound Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$12.70+0.85 (+7.17%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns MediWound's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
7 buys · 4 sales
Net bought $60.61K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| / . Deep Insight Management Ltd. | 959,652 | 10.40% | 13G (passive) amendment | Dec 31, 2023 |
| / . Israel Biotech Fund II, L.P. | 959,652 | 10.40% | 13G (passive) amendment | Dec 31, 2023 |
| Aharon Gil | 912,319 | 7.00% | 13G (passive) amendment | Dec 31, 2025 |
| Patricia Industries AB | 872,093 | 8.10% | 13D (active) | Jul 17, 2024 |
| Salamon Steven A J | 791,315 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
| Dov Yelin | 763,069 | 5.95% | 13G (passive) amendment | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 641,075 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Rosalind Advisors, Inc. | 570,326 | 5.20% | 13G (passive) amendment | Jun 30, 2025 |
| Access Industries Holdings LLC | 1,481,521 | 11.56% | 13D (active) amendment | Sep 30, 2025 |
| HOLD Alapkezelo Zrt. | 1,348,323 | 10.40% | 13G (passive) amendment | Aug 27, 2026 |
| 1,481,521 12 Check Box If The Aggregate Amount In Row (11) Excludes Certain Shares: ☐ 13 Percent Of Class Represented By Amount In Row (11): 13.8%* 14 Type Of | – | 13.80% | 13D (active) amendment | Jul 17, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shmuel Hess | COO & Chief Commercial Officer | 0 | – | Aug 28, 2026 |
| Ety Klinger | Chief Medical Officer | 1,500 | 0.01% | Mar 18, 2026 |
| Ofer Gonen | Chief Executive Officer | 8,500 | 0.07% | Mar 18, 2026 |
| Yaron Meyer | EVP, GC & Corp. Secretary | 2,357 | 0.02% | Mar 18, 2026 |
| Yaakov Aya Ben | VP Clinical & Reg. Affairs | 125 | 0.00% | Mar 18, 2026 |
| Kalfon Hana Luxenburg | Chief Financial Officer | 3,000 | 0.02% | Mar 18, 2026 |
| Samuel Rubinstein | Director | 750 | 0.01% | Sep 2, 2026 |
| Nachum Shamir | Director | 55,815 | 0.43% | Jun 4, 2026 |
| David Morton Fox | Director | 22,283 | 0.17% | Jun 2, 2026 |
| Vickie Rae Driver | Director | 750 | 0.01% | Mar 25, 2026 |
| Stephen T. Wills | Director | 750 | 0.01% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samuel Rubinstein Director | Sep 1, 2026 | Sale | −525 | $12.72 | $6.68K | 0 |
| Samuel Rubinstein Director | Sep 1, 2026 | Buy | +525 | $12.62 | $6.63K | 525 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 27, 2026 | Sale | −1,979 | $12.72 | $25.17K | 0 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 27, 2026 | Sale | −1,979 | $13.13 | $25.98K | 0 |
| Shmuel Hess COO & Chief Commercial Officer | Aug 26, 2026 | Sale | −1,865 | $13.00 | $24.25K | 0 |
| Nachum Shamir Director | Jun 3, 2026 | Buy | +5,825 | $14.00 | $81.55K | 55,815 |
| Nachum Shamir Director | Jun 3, 2026 | Buy | +175 | $13.98 | $2.45K | 49,990 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +1,797 | $14.00 | $25.16K | 22,283 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +10 | $14.23 | $142 | 20,486 |
| David Morton Fox Director | Jun 1, 2026 | Buy | +1,730 | $14.23 | $24.62K | 20,476 |
| Samuel Rubinstein Director | May 29, 2026 | Buy | +150 | $14.33 | $2.15K | 2,993 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hess Shmulik Officer | Aug 28, 2026 | 3,958 | $50.27K | Aug 27, 2026 | Shares acquired upon exercise of employee stock options |
| Shmuel Hess Officer | Dec 3, 2025 | 3,693 | $63.56K | Dec 2, 2025 | Employee Stock Option Plan |